New Delhi, Sept. 18 -- The recent imposition of a 50% tariff by the US on a range of Indian imports has raised concerns across sectors, but the pharmaceutical industry continues to demonstrate strong resilience and is poised for steady growth in the coming year, according to rating agency ICRA.
ICRA's latest review projects revenues for its sample set of pharmaceutical companies to expand by 7-9% in fiscal year (FY) 2026.
This growth is expected to be driven by an 8-10% increase in the domestic market and a robust 10-12% rise in European markets. Meanwhile, growth in the US-the largest export market-is anticipated to moderate to 3-5%, down from nearly 10% in FY2025, reflecting price pressures, regulatory scrutiny, and evolving market cond...